Low-Density Lipoprotein Removal Methods by Membranes and Future Perspectives

Artificial Organs

Volumn 20, Issue 4, 1996, Pages 346-354

  Matsuda, Yukihiro ^a   Malchesky, Paul S ^a   Nosé, Yukihiko ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

LDL apheresis; LDL removal by membrane methods; Management of atherosclerosis; Thermofiltration

Indexed keywords

CHOLESTEROL; LIPOPROTEINS; PATIENT TREATMENT;

FUTURE PERSPECTIVES; LOW DENSITY LIPOPROTEINS; LOW-DENSITY LIPOPROTEIN APHERESIS; LOW-DENSITY LIPOPROTEIN REMOVAL BY MEMBRANE METHOD; MANAGEMENT OF ATHEROSCLEROSE; MEMBRANE METHODS; MEMBRANE TECHNIQUES; REMOVAL METHOD; THERMOFILTRATION;

DISEASES;

ANIMALIA;

LOW DENSITY LIPOPROTEIN;

APHERESIS; ATHEROSCLEROSIS; HUMAN; HYPERLIPIDEMIA; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0029897182     PISSN: 0160564X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1594.1996.tb04458.x     Document Type: Review

References (37)

1. National Cholesterol Education Program. Report of the National Cholesterol Education Program Expert Panel of detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med 1988;148:36-69.
2. Brown NS, Goldstein JL. A receptor mediated pathway for cholesterol homeostasis. Science 1986;232:34-47.
3. Thompson GR, Lowenthal R, Myant NB. Plasma exchange in the management of homozygous familial hypercholesterolemia. Lancet 1975;1:1208-11.
4. Nosé Y, Usami M, Malchesky PS, Emura M, Horiuchi T, Sakamoto H, Smith JW. Clinical thermofiltration: initial application. Artif Organs 1985;9:425-7.
5. Smith LC, Massey JB, Sparrow JT, Gotto AM, Pownall HJ. Structure and dynamics of human plasma lipoproteins. In: Pifat G, Herak JN, eds. Supramolecular structure and function. New York: Plenum Press, 1983:205-44.
6. Nosé Y, Malchesky PS, Smith JW. Hybrid artificial organs: Are they really necessary? Artif Organs 1980;4:285-90.
7. Horiuchi T, Malchesky PS, Matsugane T, Abe Y, Smith JW, Sakai K, Nosé Y. Effects of temperature and plasma constituents in plasma filtration. In: Astumi K, Maekawa M, Ota K, eds. Progress in artificial organs - 1983. Cleveland: ISAO Press, 1984;2:691-7.
8. Nosé Y, Horiuchi T, Malchesky PS, Smith JW, Matsubara S, Abe Y. Therapeutic cryogel removal in autoimmune disease: what is cryogel? In: Oda T, ed. Therapeutic plasmapheresis (II). New York, Stuttgart: F.K. Schattauer Verlag, 1982:15-25.
9. Horiuchi T, Emura M, Usami M, Malchesky PS, Nosé Y. Membrane plasma filtration (MPF): effect of temperature of heparin and macromolecule sieving. Trans Am Soc Artif Intern Organs 1985;31:692-7.
10. Usami M, Horiuchi T, Emura M, Malchesky PS, Naito HK, Gerrity RG, Nosé Y. Thermal effect of LDL/HDL separation in membrane filtration: thermofiltration. Trans Am Soc Artif Intern Organs 1985;31:716-21.
11. Sueoka A, Miyahara T, Suzuki T, Ueda Y, Horiuchi T, Usami M, Malchesky PS, Nosé Y. Effect of temperature on filtration characteristics of Eval secondary filter. In: Oda T, ed. Therapeutic plasmapheresis (V): proceedings of 5th symposium on therapeutic plasmapheresis, Tokyo, 1985. Stuttgart, New York: Schattauer, 1986:87-91.
12. Nomura H, Malchesky PS, Yamashita M, Werynski A, Nosé Y. The effect of extracorporeal cholesterol removal on the progression of atherosclerosis. Trans Am Soc Artif Intern Organs 1989;35:346-8.
13. Nomura H, Malchesky PS, Goldcamp JB, Yamashita M, Werynski A, Nosé Y. Selective removal of cholesterol by plasmapheresis and the progression of atherosclerosis. J Clin Apheresis 1992;7:194-200.
14. Malchesky PS, Werynski A, Nomura H, Yamashita M, Takeyama Y, Nosé Y. Kinetic analysis of cholesterol removal by thermofiltration. Trans Am Soc Artif Intern Organs 1988;34:965-8.
15. Takeyama Y, Malchesky PS, Cressman MD, Yamashita M, Horiuchi T, Usami M, Koo AP, Pence G, Nosé Y. Removal and recovery of cholesterol in thermofiltration. Int J Artif Organs 1988;11:201-8.
16. Malchesky PS, Nomura H, Werynski A, Takeyama Y, Yamashita M, Nosé Y. Thermofiltration in hypercholesterolemia: analysis of removal and posttreatment cholesterol recovery. In: Rock G, ed. Apheresis. New York: Alan R. Liss, 1990:201-4.
17. Malchesky PS, Werynski A, Nomura H, Takeyama Y, Yamashita M, Nosé Y. Thermofiltration in hypercholesterolemia temperature: analysis of removal and posttreatment cholesterol recovery. J Clin Apheresis 1990;5:145-50.
18. Yokoyama J, Hayashi R, Satani M, Yamamoto A. Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolemia. Arteriosclerosis 1985;5:613-22.
19. Busnach G, Brando B, Zoppi F, Franceschini G, Dal Col A, Perrino ML, Minetti L. Effect of cascade filtration on normal lipid metabolism. In: Oda T, Shiokawa Y, Inoue N, eds. Proceedings of the First International Congress of World Apheresis Association: therapeutic plasmapheresis (VI). Cleveland: ISAO Press, No. 311, 1987:737-42.
20. Antwiler GD, Dau PC, Lobdell DD. Reduction of low density lipoproteins with dextran sulfate in patients with familial hypercholesterolemia. J Clin Apheresis 1988;4:18-29.
21. Borberg H, Bode C, Mattele L, Oette K, Tauchen M, Stoffel W. LDL apheresis in hypercholesterolemic patients: technical and clinical aspects. In: Lysaght MJ, Gurland HJ, eds. Plasma separation and plasma filtration. Basel: Karger, 1983:266-71.
22. Malchesky PS, Starre JJ, Wojcicki J, Werynski A. Smith JW, Abe Y, Nosé Y. Macromolecular solute kinetics in on-line membrane plasma treatment system. Cleve Clin Q 1984; 51:127-33.
23. Suehiro T, Sueoka A, Horiguchi J, Kojima S, Shiba M, Yamamoto A. Clinical evaluation of plasma pheresis using a newly developed high performance Eval secondary filter (Evaflux-5A) for hypercholesterolemia (in Japanese). Jpn J Artif Organs 1993;22:243-7.
24. Suzuki M, Yamane S, Matugane T, Nobuto T, Azuma N, Nishide T, Shinomiya M, Suito K, Sasaki N, Nosé Y. Evaluation of double filtration plasmapheresis, thermofiltration, LDL adsorptive methods by crossover test in the treatment of familial hypercholesterolemia patients. Artif Organs 1996;20:296-302.
25. Seed M, Hoppichler F, Reaveley D, McCarthy S, Thompson GR, Boerwinkle E, Utermann G. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med 1990;322:1494-9.
26. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989;339:303-5.
27. Yarnell JWG, Baker JA, Sweetnam PM, Bainton D, O'Brien JR, Whitehead PJ, Elwood PC. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. Circulation 1991;83:836-44.
28. Kannel WB, D'Agostino RB, Belanger AJ. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from the Framingham study. Am Heart J 1987;113:1006-10.
29. Thiery J, Seidel D. LDL apheresis: clinical experience and indications in the treatment of severe hypercholesterolemia. Transfus Sci 1993;14:249-59.
30. Armstrong VW, Schleef J, Thiery J, Muche R, Schuff-Werner P, Eisenhauer T, Seidel D. Effect of HELP-LDL-apheresis on serum concentrations of human lipoprotein(a): kinetic analysis of the post-temperature return to baseline levels. Eur J Clin Invest 1989;19:235-40.
31. Daida H, Lee YJ, Yokoi H, Kanoh T, Ishiwata S, Kato K, Nishikawa H, Takatsu F, Kato H, Kutsumi Y, Yamada N, Noma A, Yamaguchi H, the Low-Density Lipoprotein Apheresis Angioplasty Restenosis Trial (L-ART) Group. Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein(a) levels with low-density lipoprotein apheresis. Am J Cardiol 1994;73:(15): 1037-40.
32. Agishi T, Naganuma S, Nakasato S, Kitajima K, Ota K, Ban K, Nomura M. Treatment of arteriosclerotic obstruction by LDL adsorption. Angiology 1993; 3:222-7.
33. Dormandy JA, Hoare E, Colley J, Arrowsmith DE, Dormandy TL. Clinical heamodynamic, rheological, and biochemical findings in 126 patients with intermittent claudication. BMJ 1973;4:576-81.
34. Lassila R, Peltonen S, Lepäntalo M, Saarinen O, Kauhanen P, Manninen V. Severity of peripheral atherosclerosis is associated with fibrinogen and degradation of cross-linked fibrin. Arteriosclerosis and Thrombosis 1993;13:1738-42.
35. Tyrrel J, Cooke T, Reilly M, Colgan M, Moore D, Shanik DG, Bergin C, Feely J. Lipoprotein (a) [Lp(a)] and peripheral vascular disease. J Intern Med 1992;232:349-52.
36. Wildmann MD, Sumpio BE. Lipoprotein (a): a risk factor for peripheral vascular disease. Ann Vase Surg 1993;7:446-51.
37. Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein (a). Science 1993;260:1655-8.